Prostate Cancer News and Research

Latest Prostate Cancer News and Research

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

4 Nov 2010

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known as salvage radiation therapy. Researchers at Fox Chase have now determined a better way to monitor outcomes after this procedure.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.

4 Nov 2010

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

When Medicare policy changes led to reductions in reimbursement for hormonal treatment of prostate cancer, there was a sharp decline in its use among patients not likely to benefit from the treatment. But among patients for whom the therapy is clearly beneficial, doctors continued to prescribe it at the same rate, according to a new study.

4 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of feasibility studies aimed at improving delivery of cancer drugs using a combination of ultrasound sensitive liposomes and High Intensity Focused Ultrasound (HIFU).

3 Nov 2010

AHRQ study finds prostate cancer mortality rate declines by 45%

According to the U.S. Agency for Healthcare Research and Quality (AHRQ), compared to men in 1999, American men in 2006 that were fighting prostate cancer were 45% less likely to die from the disease.

3 Nov 2010

New technique could help scientists to predict how living prostate tissues respond to therapy

Scientists at the Johns Hopkins Kimmel Cancer Center, University of Helsinki and Stanford University have developed a technique to keep normal and cancerous prostate tissue removed during surgery alive and functioning normally in the laboratory for up to a week.

3 Nov 2010

Image Guided IMRT preserves sexual function in men after prostatectomy

Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

3 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Staff member of U.S. preventive services task force quits over cancelled meeting

A member of the support staff for the United States Preventive Services Task Force has quit over the cancellation of a meeting scheduled for today and tomorrow at which the task force was due to vote on the controversial issue of prostate-cancer screening.

3 Nov 2010

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

CytRx Corporation a biopharmaceutical company specializing in oncology, today announced that it has been awarded a nontaxable grant of approximately $735,000 related to its INNO-206, tamibarotene and bafetinib programs under the Qualifying Therapeutic Discovery Project Program included in the Patient Protection and Affordable Care Act, H.R. 3590, signed into law in March 2010.

3 Nov 2010

Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial

Soligenix, Inc., a late-stage biopharmaceutical company, reported today that it has completed enrollment of its Phase 1B clinical trial of RiVax™, a ricin subunit vaccine, in healthy volunteers. Preliminary results indicate that RiVax™ appears safe at all doses tested in volunteers. This trial is designed to assess the duration of immune responses using an adjuvant formulation of RiVax™ over a period of more than one year after vaccination.

2 Nov 2010

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

The Department of Veterans Affairs (VA) has begun distributing disability benefits to Vietnam Veterans who qualify for compensation under recently liberalized rules for Agent Orange exposure.

2 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

$Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients$

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

NWBT receives $490,000 in two grants under QTDP program

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Gene fusion prostate cancers susceptible to secondary mutations

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

Top 10 Medical Innovations for 2011

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

AHRQ study finds prostate cancer mortality rate declines by 45%

New technique could help scientists to predict how living prostate tissues respond to therapy

Image Guided IMRT preserves sexual function in men after prostatectomy

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Staff member of U.S. preventive services task force quits over cancelled meeting

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

ArcticDx develops test to determine inherited risk for AMD

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in